The Undercovered Dozen series spotlights 12 lesser-covered stocks featured on Seeking Alpha between June 5 and June 11. This curated selection aims to provide fresh investment ideas and foster community discussion around under-the-radar equities. Readers are encouraged to engage, share perspectives, and highlight additional overlooked investment opportunities.
Apogee Therapeutics NASDAQ: APGE executives outlined plans to advance zumilokibart, the company's IL-13-targeting antibody, into late-stage development for atopic dermatitis while expanding the program into asthma and eosinophilic esophagitis, during a Goldman Sachs discussion hosted by lead biotechnology equity research analyst Salveen Richter.
Blackstone Inc. (BX) is rated a Buy, offering quality growth at discounted valuations despite sector-wide private credit concerns. BX's diversified model, robust credit underwriting, and focus on investment-grade secured debt position it to absorb private credit shocks better than peers. Key growth catalysts in AI/data center infrastructure, 401(k) regulatory changes, and perpetual capital, are not fully priced into BX shares.
| Capital Markets Industry | Financials Sector | Stephen Allen Schwarzman CEO | XETRA Exchange | US09260D1072 ISIN |
| US Country | 4,895 Employees | 4 May 2026 Last Dividend | - Last Split | - IPO Date |
Founded in 1985 and headquartered in New York, New York, Blackstone Inc. is a leading alternative asset management firm with a broad portfolio of investment strategies and a global presence. With additional offices across Asia, Europe, North America, and Central America, the firm has established itself as a major player in the investment world, focusing on a range of sectors such as real estate, private equity, hedge funds, credit, and more. Blackstone Inc. is renowned for its ability to invest in early-stage companies, provide comprehensive capital markets services, and manage a diverse array of asset classes, making it a versatile and powerful financial institution.
Blackstone's real estate segment is particularly noted for its focus on opportunistic, core+ investments, and debt opportunities collateralized by commercial real estate. The firm operates globally, targeting stabilized income-oriented commercial properties across North America, Europe, and Asia.
Its corporate private equity business is active worldwide, engaging in large buyouts, special situations, distressed mortgage loans, mid-cap buyouts, and buy and build platforms. These involve multiple acquisitions under a singular management team and platform, aiming for significant majority or minority investments in operating companies across various sectors including healthcare, financial services, technology, and consumer markets.
Blackstone manages a wide range of commingled and customized fund solutions through its hedge fund business. This includes investments in a broad spectrum of strategies to cater to the diverse needs of its clients.
The firm’s credit business focuses on investments across the capital structure of non-investment grade companies. This includes senior debt, subordinated debt, preferred stock, and common equity, offering a comprehensive range of credit solutions to its clients.
Blackstone provides innovative investment solutions through its secondary funds of funds, offering investors exposure to a diversified portfolio of assets.
Investing across public debt and equity markets, Blackstone seeks opportunities that offer attractive risk-adjusted returns for its investors, leveraging its extensive market research and risk management capabilities.
The firm offers multi-asset class strategies, providing clients with a broad mix of equity and fixed income securities to meet their diverse investment objectives and risk tolerance.
Apart from its investment activities, Blackstone also provides a range of capital markets services. These include facilitating access to capital for corporations, optimizing their capital structure, and assisting in the execution of institutional trading strategies.